Crossmark

Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study

Crossref DOI link: https://doi.org/10.1007/s40121-022-00652-6

Published Online: 2022-05-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hsieh, Szu-Min

Chang, Shan-Chwen

Cheng, Hao-Yuan

Shih, Shin-Ru

Lien, Chia En https://orcid.org/0000-0003-4703-6628
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04487210 at ClinicalTrials.gov

Documents that mention this clinical trial

Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study
https://doi.org/10.1007/s40121-022-00652-6
Funding

Funding for this research was provided by:

Taiwan Centers for Disease Control, Ministry of Health and Welfare Prevention

Medigen Vaccine Biologics Corporation
License Information

Text and Data Mining valid from 2022-05-17

Version of Record valid from 2022-05-17
More Information

Article History

Received: 9 February 2022

Accepted: 27 April 2022

First Online: 17 May 2022

Document is current

Any future updates will be listed below